Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma.

ABSTRACT:

Background

Relapsed high-grade glioma has dismal outcomes. Mebendazole has shown promising activity against glioma in in-vitro and in-vivo studies. Hence, we undertook a phase 1 study to repurpose mebendazole in the treatment of glioblastoma.

Methods

We conducted a phase 1 study (accelerated titrated design 4) of mebendazole in patients with recurrent glioblastoma (GBM). Patients eligible for re-irradiation were enrolled in arm A1 (radiation with concurrent temozolomide 75 mg/m² daily during the course of radiation+mebendazole) while patients who were ineligible were enrolled in either arm B1 (CCNU 110 mg/m² day 1, every 6 weekly + mebendazole) or arm C1 (temozolomide 200 mg/m² day 1-5, every 4 weekly + mebendazole). The primary endpoint of p

SUBMITTER: Patil VM 

PROVIDER: S-EPMC7333848 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature